Federal Appeals Court Backs Subpoena of Doctors Providing Sex-Change Treatments for Minors
A federal appeals court has ruled in favor of the Trump administration, allowing subpoenas to be issued to doctors and clinics that administer sex-change drugs and surgeries to minors.
Previously, last year, the Department of Justice (DOJ) declared that it had issued over 20 subpoenas as part of its investigation into potential medical fraud related to these treatments. However, efforts to enforce these subpoenas had faced obstacles in federal courts, according to reports.
The Ninth Circuit Court of Appeals recently overturned a lower court’s decision that had blocked a subpoena to a telemedicine clinic named “QueerDoc,” instructing the case to return to the lower court for further examination.
The court noted that the long-term risks associated with sex-changing drugs for minors are “uncertain,” emphasizing that the president can direct the Justice Department to enforce laws aligned with his policies.
Judge Carlos Bee, appointed by former President George W. Bush, remarked that just as every president has their own policy priorities, they also have law enforcement focuses connected to these policies.
The majority opinion, which included Trump-nominated Justice Daniel Brace, suggested that gender reassignment treatments for minors are part of an “unresolved scientific debate,” allowing the Trump administration to position its opposition on ethical and philosophical grounds.
The subpoena specifically seeks records from QueerDoc, including personnel files, billing documents, and information on patients who have been prescribed puberty blockers and cross-sex hormones. The Associated Press provided details about these records.
Adrian Leavitt, an attorney with the American Civil Liberties Union (ACLU), plans to challenge the subpoena in court. QueerDoc argues that it is overly broad and presents a burden, whereas the Justice Department asserts that the clinic might be misleading the public regarding the effects of sex-change drugs.
President Trump had previously signed an executive order emphasizing “biological reality” and discontinuing federal funding for minors’ gender transition procedures, directing the DOJ to prioritize investigations into any violations of drug safety laws.
Concerns exist around the side effects of sex reassignment treatments, which may include irreversible surgeries and infertility. These treatments often involve procedures like mastectomies, genital removal, hormone therapy, and puberty blockers—which might affect bone growth, according to research.
Some individuals who engaged in these treatments as minors have since sought to reverse their decisions, sharing experiences of physical and emotional distress resulting from the procedures.
Dubbed “gender-affirming care,” there is a significant push from various governmental and academic institutions to promote sex-transition treatments for minors. The Biden administration is actively advocating for minors to access these drugs and surgeries.
While proponents argue that these interventions can decrease suicide rates and improve mental health among minors, the credibility of these claims is increasingly questioned as research emerges that suggests otherwise.
Reports additionally indicate that political influences have seeped into the realm of gender medicine, raising further concerns about practices within major hospitals and health organizations, especially as the guidelines from the World Professional Association for Transgender Health (WPATH) have sparked controversies regarding age limits for medical interventions.
Studies suggest a high likelihood that children who experience gender confusion will naturally outgrow it by adulthood, raising questions about the long-term impacts of these treatments, especially as some European nations have begun reversing their approaches to minors’ sex-change treatments.
